

Express Mail Mailing Label No. EV926974940US

SHEET 1 OF 2

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: WYE-024 APPLICANT(S): Burczynski <i>et al.</i> SERIAL NO.: 10/775,169 FILING DATE: February 11, 2004 GROUP NO.: 1636 /Hibbert
--	---

U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
/C.H./	AA	2004/0018528	01/29/2004	Morimoto <i>et al.</i>			

OTHER ART, JOURNAL ARTICLES, ETC.


EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)						
/C.H./	CA	Bae <i>et al.</i> *(2000), "The Detection of Circulating Breast Cancer Cells in Peripheral Blood by Reverse Transcriptase-Polymerase Chain Reaction," <u>J. Korean Med Sci</u> , 15:194-198.					
/C.H./	CB	Results of Blast, (2006), http://www.ncbi.nlm.nih.gov/blast/Blast.cgi , p. 1-16.					
/C.H./	CC	Cao <i>et al.</i> , (1994), "Human Gastric Adenocarcinoma Cathepsin B: Isolation and Sequencing of Full-Length cDNAs and Polymorphisms of the Gene," <u>Gene</u> , 1 pg-abstract only.					
/C.H./	CD	Deprimo <i>et al.</i> , (2003), "Expression Profiling of Blood Samples from an SU5416 Phase III Metastatic Colorectal Cancer Clinical Trial: a Novel Strategy for Biomarker Identification," <u>Biomed Central</u> , 1-16.					
/C.H./	CE	Enard <i>et al.</i> , (2002), "Intra- and Interspecific Variation in Primate Gene Expression Patterns," <u>Science</u> , p. 340-343.					
/C.H./	CF	GenBank, (1999), Locus: HUMCYCLORA, Accession: L04288, p. 1-4.					
/C.H./	CG	Hidalgo <i>et al.</i> , (2000), "The Rapamycin-Sensitive Transduction Pathway as a Target for Cancer Therapy," <u>Oncogene</u> , 19:6680-6686.					
/C.H./	CH	Hill <i>et al.</i> , (2001), "Evaluation of Normalization Procedures for Oligonucleotide Array Data Based on Spiked cRNA Controls," <u>Genome Biology</u> , 2(12):research0055.1-0055.13.					
/C.H./	CI	Kaempfer <i>et al.</i> , (1996), "Prediction of Response to Treatment in Superficial Bladder Carcinoma Through Pattern of Interleukin-2 Gene Expression," <u>J. Clin. Oncol.</u> , 14:1778-1786.					
/C.H./	CJ	Liu <i>et al.</i> , (2001), "Upregulation of Toll-Like Receptor 2 Gene Expression in Macrophage Response to Peptidoglycan and High Concentration of Lipopolysaccharide Is Involved in NF- κ B Activation," <u>Infection and Immun.</u> , 69:2788-2796.					
/C.H./	CK	Olive <i>et al.</i> , (1998), "Expression of Cytokine mRNA Transcripts in Renal Cell Carcinoma," <u>Immun. And Cell Biol.</u> , 76:357-362.					
/C.H./	CL	Panelli <i>et al.</i> , (2002), "Gene-Expression Profiling of the Response of Peripheral Blood Mononuclear Cells and Melanoma Metastases to Systematic IL-2 Administration," <u>Genome Biology</u> , 3(7):research0035.1-0035.17.					

EXAMINER /Catherine Hibbert/	DATE CONSIDERED 09/17/2007
-------------------------------------	-----------------------------------

FORM PTO - 1449		ATTORNEY DOCKET NO.: WYE-024
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Burczynski <i>et al.</i>
		SERIAL NO.: 10/775,169
		FILING DATE: February 11, 2004
		GROUP NO.: 1636
/C.H./	CM	Park <i>et al.</i> , (2002), "Identification of Radiation-Specific Responses From Gene Expression Profile," <u>Oncogene</u> , 21:5421-8528.
/C.H./	CN	Thisted, (1998), "What Is A P-Value?" www.stat.uchicago.edu/~thisted , p. 1-6.
/C.H./	CO	Van 't Veer <i>et al.</i> , (2002), "Gene Expression Profiling Predicts Clinical Outcome of Breast Cancer," <u>Nature</u> , 415:530-536.
/C.H./	CP	Yeang <i>et al.</i> , (2001), "Molecular Classification of Multiple Tumor Types," <u>Bioinformatics</u> , 17:Suppl. S316-S322.
/C.H./	CQ	Zwicky <i>et al.</i> , (2002), "Cathepsin B Expression and Down-Regulation by Gene Silencing and Antisense DNA in Human Chondrocytes," <u>Biochem J.</u> , 367:209-217.
/C.H./	CR	PCT International Search Report for International Application No.: PCT/US04/004118 (Date of mailing 1/19/2005).
/C.H./	CS	PCT International Search Report for International Application No.: PCT/US04/013587 (Date of mailing 1/25/2005).
/C.H./	CT	PCT International Search Report for International Application No.: PCT/US06/005772 (Date of mailing 8/11/2006).

BOS-1100869 v1

EXAMINER /Catherine Hibbert/	DATE CONSIDERED 09/17/2007
-------------------------------------	-----------------------------------



SUBSTITUTE for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known Application Number 10/775,169 Filing Date February 11, 2004 First Named Inventor M. E. BURCZYNSKI <i>et al.</i> Art Unit 1636 1634 Examiner Name Hibbert Sarae L. Bausch Attorney Docket Number 031896-013000 (AM101080)	
Sheet	1	of	3

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
/C.H./		U.S. - 6,288,220	09-11-2001	KAMBARA, H. <i>et al.</i>	
		U.S. - 6,391,562	05-21-2002	KAMBARA, H. <i>et al.</i>	
		U.S. - 6,303,301	10-16-2001	MACK, D. H. <i>et al.</i>	
		U.S. - 6,087,098	06-11-2000	MCKIERNAN, J. M. <i>et al.</i>	
		U.S. - 5,840,506	11-24-1998	GIORDANO, A.	
		U.S. - 6,110,675	08-29-2000	COHEN, M. <i>et al.</i>	
		U.S. - 6,190,857	02-20-2001	RALPH, D. <i>et al.</i>	
		U.S. - 6,317,731	11-13-2001	LUCIANO, J. S.	
		U.S. - 2001/0053548 A1	12-20-2001	RYBAK, M. E. <i>et al.</i>	
		U.S. - 2002/0042072 A1	04-11-2002	VAN MEEL, J. <i>et al.</i>	
		U.S. - 2002/0132274 A1	09-19-2002	NEVALAINEN, M. T. <i>et al.</i>	
		U.S. - 2002/0164664 A1	11-07-2002	HLAVATY, J. J. <i>et al.</i>	
		U.S. - 2002/0168638 A1	11-14-2002	SCHLEGEL, R. <i>et al.</i>	
		U.S. - 2002/0182614 A1	12-05-2002	GILLIS, K. <i>et al.</i>	
		U.S. - 6,647,341	11-11-2003	GOLUB, T. R. <i>et al.</i>	
		U.S. - 2004/0110221 A1	06-10-2004	TWINE, N. C. <i>et al.</i>	
		U.S. - 2004/0235020 A1	11-25-2004	BURCZYNSKI, M. E. <i>et al.</i>	
		U.S. - 60/427,982		BURCZYNSKI, M. E. <i>et al.</i>	
		U.S. - 60/459,782		TWINE, N. C. <i>et al.</i>	
		U.S. - 60/446,133		BURCZYNSKI, M. E. <i>et al.</i>	
		U.S. - 60/538,246		BURCZYNSKI, M. E. <i>et al.</i>	
/C.H./		U.S. - 60/466,067		DORNER, A. <i>et al.</i>	

Examiner Signature	Date Considered
-----------------------	--------------------

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ Number ⁴ Kind Code ² (if known)				
/C.H./		WO 2002/40717 A2	05-23-2002	MOHANLAL, R.W. <i>et al.</i>		
/C.H./		WO 2000/63364 A2	10-26-2000	PACHUK, C. <i>et al.</i>		
/C.H./		WO 2004/048933 A2	06-10-2004	BURCZYNSKI, M. <i>et al.</i>		
/C.H./		WO 2004/094673 A2	11-04-2004	BURCZYNSKI, M. <i>et al.</i>		
/C.H./		WO 2004/097052 A2	11-11-2004	BURCZYNSKI, M. <i>et al.</i>		

Examiner Signature	/Catherine Hibbert/	Date Considered	09/17/2007
-----------------------	---------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/775,169
		Filing Date	February 11, 2004
		First Named Inventor	M. E. BURCZYNSKI <i>et al.</i>
		Art Unit	1634
		Examiner Name	Sarae L. Bausch
Sheet 2	of 3	Attorney Docket Number	031896-013000 (AM101080)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/C.H./		International Search Report for PCT/US2004/004118, mailed 01/19/2005, 9 sheets	
		International Search Report for PCT/US2004/013587, mailed 01/25/2005, 9 sheets	
		International Search Report for PCT/US2003/037481, mailed 08/23/2005, 3 sheets	
		A. H. KIBBE, Handbook of Pharmaceutical Excipients, 3 rd Edition, Pharmaceutical Press, London, U.K., 2000	
		Affymetrix GeneChip® Expression Analysis, Data Analysis Fundamentals	
		Affymetrix GeneChip® Expression Analysis Technical Manual	
		ARMSTRONG, S. A. <i>et al.</i> , MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia, <i>Nat. Genet.</i> , 30(1):41-47, 2002	
		BOSMA, A. J. <i>et al.</i> , Detection of circulating breast tumor cells by differential expression of marker genes, <i>Clin. Cancer Res.</i> , 8(6):1871-1877, 2002	
		COX, D. R., Regression models and life-tables, <i>Meeting of the Research Section of the Royal Statistical Society</i> , pp. 187-220, 1972	
		DAVIS, I. J. <i>et al.</i> , Cloning of an <i>Alpha-TFEB</i> fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation, <i>Proc. Natl. Acad. Sci. USA</i> , 100(10):6051-6056, 2003	
		DEPRIMO, S.E. <i>et al.</i> , Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification, <i>BMC Cancer</i> , 3(3):1-12, 2003	
		EISEN, M. B. <i>et al.</i> , Cluster analysis and display of genome-wide expression patterns, <i>Proc. Natl. Acad. Sci. USA</i> , 95:14863-14868, 1998	
		GOLUB, T. R. <i>et al.</i> , Molecular classification of cancer: class discovery and class prediction by gene expression monitoring, <i>Science</i> , 286(15):531-537, 1999	
		HILL, A. A. <i>et al.</i> , Genomic analysis of gene expression in <i>C. elegans</i> , <i>Science</i> , 290:809-812, 2000	
		HILL, A. A. <i>et al.</i> , Evaluation of normalization procedures for oligonucleotide array data based on spiked cRNA controls, <i>Genome Biology</i> , 2 (12):1-13, 2001	
		KOVACS, G. <i>et al.</i> , The Heidelberg classification of renal cell tumours, <i>J. Pathol.</i> , 183(2):131-133, 1997	
		LICHTENFELS, R. <i>et al.</i> , Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses, <i>Biochim Biophys Acta.</i> , 1646 (1-2):21-31, 2003	
✓		LOCKHART, D. J. <i>et al.</i> , Expression monitoring by hybridization to high-density oligonucleotide arrays, <i>Nat. Biotechnol.</i> , 14(13):1675-1680, 1996	
/C.H./		MOTZER, R. J. <i>et al.</i> , Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma, <i>J. Clin. Oncol.</i> , 17(8):2530-2540, 1999	

Examiner Signature	/Catherine Hibbert/	Date Considered	09/17/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/775,169		
		Filing Date	February 11, 2004		
		First Named Inventor	M. E. BURCZYNSKI <i>et al.</i>		
		Art Unit	1634		
		Examiner Name	Sarae L. Bausch		
Sheet	3	of	3	Attorney Docket Number	031896-013000 (AM101080)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/C.H./		PAI, S. M. <i>et al.</i> , Population pharmacokinetic analysis of didanosine (2',3'-dideoxyinosine) plasma concentrations obtained in phase I clinical trials in patients with AIDS or AIDS-related complex, <i>J. Clin. Pharmacol.</i> , 32(3):242-247, 1992	
/C.H./		PARK, W.Y. <i>et al.</i> , Identification of radiation-specific responses from gene expression profile, <i>Oncogene</i> , 21(55):8521-8528, 2002	
/C.H./		PERALBA, J.-M. <i>et al.</i> , Pharmacodynamic evaluation of the rapamycin ester CCI-779, <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> , Volume 43, March 2002 (2002-2003), pp. 1000-1001, Abstract No. 4961, and 93 rd Annual Meeting of the American Association for Cancer Research, San Francisco, CA, April 06-10, 2002	
/C.H./		POMEROY, S. L. <i>et al.</i> , Supplemental Information for Nature's Paper: Prediction of central nervous system embryonal tumour outcome based on gene expression, pp. 1-104, 2002	
/C.H./		POMEROY, S. L. <i>et al.</i> , Prediction of central nervous system embryonal tumour outcome based on gene expression, <i>Nature</i> , 415(6870):436-442, 2002	
/C.H./		RAMASWAMY, S. <i>et al.</i> , Multiclass cancer diagnosis using tumor gene expression signatures, <i>Proc. Natl. Acad. Sci. USA</i> , 98(26):15149-15154, 2001	
/C.H./		SLONIM, D. K. <i>et al.</i> , Class prediction and discovery using gene expression data, <i>Proceedings of the Fourth Annual International Conference on "Computational Molecular Biology,"</i> TOKYO, JAPAN, pp. 263-272, 2000	
/C.H./		SNEDECOR, G. W. <i>et al.</i> , Correlation, In <i>Statistical Methods</i> , Eighth Edition, Chapter 10, pp. 177-195, Iowa State University Press, Ames, Iowa, 1989	
/C.H./		SU, A. I. <i>et al.</i> , Molecular classification of human carcinomas by use of gene expression signatures, <i>Cancer Res.</i> , 61:7388-7393, 2001	
/C.H./		VAN DE VIJVER, M. J. <i>et al.</i> , A gene-expression signature as a predictor of survival in breast cancer, <i>N. Engl. J. Med.</i> , 347(25):1999-2009, 2002	
/C.H./		WHO Handbook for Reporting Results of Cancer Treatment, WHO Offset Publication No. 48, pp. 1-45, World Health Organization, Geneva, Switzerland, 1979	

Examiner Signature	/Catherine Hibbert/	Date Considered	09/17/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/775,169		
		Filing Date	February 11, 2004		
		First Named Inventor	Michael E. Burczynski et al.		
		Art Unit	1636		
		Examiner Name	Not Yet Assigned Hibbert		
Sheet	1	of	2	Attorney Docket Number	031896-013000 (AM101080)


U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number ⁴ Kind Code ² (if known)			
/C.H./			WO00/040749	07-13-00	Chin	
/C.H./			WO02/040000	05-23-02	Dukart et al.	
/C.H./			WO01/081916	11-01-01	Ma et al.	
/C.H./			WO03/032813	04-24-03	Gerritsen et al.	
/C.H./			WO04/072265	08-26-04	Donner et al.	
/C.H./			WO04/048933	06-10-04	Stover et al.	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/C.H./		BURCZYNSKI et al., "Pharmacogenomic expression profiling of renal cell carcinoma in a phase II trial of CCI-779: identification of surrogate markers of disease and predictors of outcome in the compartment of peripheral blood", <i>European Journal of Cancer, Pergamon Press, Oxford, GB</i> , Vol. 38, November 2002, page S51	
/C.H./		SCHULZE-KOOPS, H., et al., "Persistent reduction in IL-6 mRNA in peripheral blood mononuclear cells of patients with rheumatoid arthritis after treatment with a monoclonal antibody to CD54 (ICAM-1)," <i>Clinical and Experimental Immunology</i> , Vol. 106, No. 2, November 1996, pages 190-196	
/C.H./		DIPAOLA, R. S., et al., "Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies," <i>Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology</i> , Vol. 17, No. 7, July 1999, pages 2213-2218	
/C.H./		"Product Catalogue", <i>Affymetrix</i> , January 2002, page 1	
/C.H./		SU, A. I., et al., "Molecular classification of human carcinomas by use of gene expression signatures", <i>Cancer Research</i> , Vol. No. 20, October 15, 2001, pages 7388-7393	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/775,169
				Filing Date	February 11, 2004
				First Named Inventor	Michael E. Burczynski et al.
				Art Unit	1631
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	031896-013000 (AM101080)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/C.H./		ELIT, LAURIE, "CCI-779 Wyeth", <i>Current Opinion in Investigational Drugs</i> , Vol. 3, No. 8, August 2002, pages 1249-1253	
/C.H./		RINIGER, J. A. et al., "Differential gene expression technologies for identifying surrogate markers of drug efficacy and toxicity", <i>Drug Discovery Today</i> , Vol. 5, No. 12, December 1, 2000, pages 560-568	
/C.H./		PERALBA, JOSEP MARIA et al., "Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients", <i>Clinical Cancer Research: An Official Journal of the American Association for Cancer Research</i> , Vol. 9, No. 8, August 1, 2003, pages 2887-2892	
/C.H./		SU, ANDREW I., et al., "Large-scale analysis of the human and mouse transcriptomes," <i>Proceedings of the National Academy of Sciences of the United States of America</i> , Vol. 99, No. 7, April 2, 2002, pages 4465-4470	
/C.H./		PCT International Search Report; PCT/US2004/006601; November 19, 2004; 4 pages	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

/Catherine Hibbert/

09/17/2007